Drug Information

Drug General Information
Drug ID
D0L6SS
Former ID
DNCL002508
Drug Name
BPX-101
Drug Type
Vaccine
Indication Prostate cancer [ICD9: 185; ICD10:C61] Phase 1 [522616]
Company
Bellicum Pharmaceuticals
Target and Pathway
Target(s) Tumor necrosis factor ligand superfamily member 5 Target Info [544241]
KEGG Pathway Cytokine-cytokine receptor interaction
NF-kappa B signaling pathway
Cell adhesion molecules (CAMs)
T cell receptor signaling pathway
Intestinal immune network for IgA production
Malaria
Toxoplasmosis
Asthma
Autoimmune thyroid disease
Systemic lupus erythematosus
Allograft rejection
Primary immunodeficiency
Viral myocarditis
NetPath Pathway IL2 Signaling Pathway
TNFalpha Signaling Pathway
TCR Signaling Pathway
Pathway Interaction Database IL4-mediated signaling events
CD40/CD40L signaling
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
Beta2 integrin cell surface interactions
Calcium signaling in the CD4+ TCR pathway
Reactome Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
TNFR2 non-canonical NF-kB pathway
TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway
WikiPathways Inflammatory Response Pathway
Allograft Rejection
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
References
Ref 522616ClinicalTrials.gov (NCT00868595) MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer. U.S. National Institutes of Health.
Ref 544241Activation of antigen-exposed iMC-DCs at the ??ight place??and ??ight time??promotes potent anti-tumor immunity. Oncoimmunology. 2012 May 1; 1(3): 362-363.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.